These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31784749)

  • 1. Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses.
    Markowitz LE; Naleway AL; Klein NP; Lewis RM; Crane B; Querec TD; Hsiao A; Aukes L; Timbol J; Weinmann S; Liu G; Steinau M; Unger ER
    J Infect Dis; 2020 Mar; 221(6):910-918. PubMed ID: 31784749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
    Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
    Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
    Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
    JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination.
    Markowitz LE; Naleway AL; Lewis RM; Crane B; Querec TD; Weinmann S; Steinau M; Unger ER
    Vaccine; 2019 Jun; 37(29):3918-3924. PubMed ID: 31160099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
    Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
    JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
    D'Addario M; Redmond S; Scott P; Egli-Gany D; Riveros-Balta AX; Henao Restrepo AM; Low N
    Vaccine; 2017 May; 35(22):2892-2901. PubMed ID: 28455170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
    Oliver SE; Unger ER; Lewis R; McDaniel D; Gargano JW; Steinau M; Markowitz LE
    J Infect Dis; 2017 Sep; 216(5):594-603. PubMed ID: 28931217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
    Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
    Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
    Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
    Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Delayed Human Papillomavirus Vaccination in Inner-City Adolescent Women.
    Schlecht NF; Diaz A; Shankar V; Szporn AH; Wu M; Nucci-Sack A; Peake K; Strickler HD; Burk RD
    J Infect Dis; 2016 Dec; 214(12):1952-1960. PubMed ID: 27738056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
    Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
    Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
    Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C
    Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
    Guo F; Hirth JM; Berenson AB
    Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
    Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
    Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.